Laurus Labs US arm gets 1 USFDA observation
Andhra Pradesh: Laurus Labs has announced that Laurus Generics Inc., a wholly-owned foreign subsidiary of the company, located in Berkeley Heights, New Jersey, USA has received one observation from the US Food and Drug Administration (USFDA) after a Post-marketing Adverse Drug Experience (PADE) inspection.
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Laurus Labs marketed products worldwide.
The inspection was conducted for four days between 13th January, 2025 to 21st January, 2025.
"We have been issued a Form 483 with one observation and the Company will address the said observation within stipulated timelines," the company stated in a BSE filing.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.